RUNX1 and acute myeloid leukemia: In human AML, the AML1-ETO  oncoprotein disrupts epigenetic programming through recruitment of histone deacetylase complexes (HDAC), which can be pharmacologically targeted by HDAC inhibitors such as trichostatin A (TSA).